Suppr超能文献

局灶节段性肾小球硬化症中的通透性因素

Permeability factors in focal and segmental glomerulosclerosis.

作者信息

Reiser Jochen, Nast Cynthia C, Alachkar Nada

机构信息

Department of Medicine, Rush University School of Medicine, Chicago, IL; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; and Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD.

Department of Medicine, Rush University School of Medicine, Chicago, IL; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; and Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010.

Abstract

Focal and segmental glomerulosclerosis (FSGS) represents a group of glomerular disorders, identified on kidney biopsy, that progress in the histopathologic pattern of sclerosis in parts of some glomeruli. Damage to podocytes usually marks the beginning of the disease, most evident in primary FSGS. In addition to genetic predisposition, there are many acquired causes that disturb normal podocyte homeostasis and allow for the development of FSGS. The aim of this review was to summarize recent findings of the most relevant circulating permeability factors that may serve as biomarkers of active primary idiopathic FSGS and aid in the diagnosis and prediction of recurrent FSGS after kidney transplantation.

摘要

局灶节段性肾小球硬化(FSGS)是一组经肾活检确诊的肾小球疾病,其特征为部分肾小球出现硬化的组织病理学模式。足细胞损伤通常是该疾病的起始标志,在原发性FSGS中最为明显。除了遗传易感性外,还有许多后天因素会扰乱正常的足细胞内环境稳定,从而导致FSGS的发生。本综述的目的是总结近期有关最相关循环通透性因子的研究结果,这些因子可能作为活动性原发性特发性FSGS的生物标志物,并有助于肾移植后复发性FSGS的诊断和预测。

相似文献

1
Permeability factors in focal and segmental glomerulosclerosis.
Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010.
2
Soluble urokinase receptor and focal segmental glomerulosclerosis.
Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32. doi: 10.1097/MNH.0b013e328354a681.
4
Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.
Nephron. 2020;144 Suppl 1:65-70. doi: 10.1159/000510748. Epub 2020 Dec 1.
5
Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2342-2354. doi: 10.1016/j.bbadis.2017.06.010. Epub 2017 Jun 16.
6
suPAR and chronic kidney disease-a podocyte story.
Pflugers Arch. 2017 Aug;469(7-8):1017-1020. doi: 10.1007/s00424-017-2026-7. Epub 2017 Jul 8.
7
The pathogenesis of focal segmental glomerulosclerosis.
Adv Chronic Kidney Dis. 2014 Sep;21(5):408-16. doi: 10.1053/j.ackd.2014.05.009.

引用本文的文献

2
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety.
Kidney Med. 2024 Apr 26;6(6):100833. doi: 10.1016/j.xkme.2024.100833. eCollection 2024 Jun.
3
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032. eCollection 2024 Apr.
4
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial.
Kidney Int Rep. 2023 Aug 4;8(10):2017-2028. doi: 10.1016/j.ekir.2023.07.022. eCollection 2023 Oct.
5
Urinary SPP1 has potential as a non-invasive diagnostic marker for focal segmental glomerulosclerosis.
FEBS Open Bio. 2023 Nov;13(11):2061-2080. doi: 10.1002/2211-5463.13704. Epub 2023 Sep 27.
7
Lupus podocytopathy superimposed on diabetic glomerulosclerosis: A case report.
Medicine (Baltimore). 2021 Sep 17;100(37):e27077. doi: 10.1097/MD.0000000000027077.
8
Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.
Clin Kidney J. 2020 Aug 11;14(2):482-491. doi: 10.1093/ckj/sfaa110. eCollection 2021 Feb.

本文引用的文献

1
De novo glomerular diseases after renal transplantation.
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1479-87. doi: 10.2215/CJN.12571213. Epub 2014 Apr 3.
5
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Kidney Int. 2014 Mar;85(3):636-40. doi: 10.1038/ki.2013.505. Epub 2014 Jan 8.
6
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Pediatr Nephrol. 2014 Aug;29(8):1363-71. doi: 10.1007/s00467-013-2679-1. Epub 2013 Nov 22.
7
Is there clinical value in measuring suPAR levels in FSGS?
Clin J Am Soc Nephrol. 2013 Aug;8(8):1273-5. doi: 10.2215/CJN.06170613. Epub 2013 Jul 25.
8
suPAR and FSGS: the gap between bench and bedside.
Transplantation. 2013 Aug 27;96(4):368-9. doi: 10.1097/TP.0b013e31829e6d40.
10
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验